Clinical Trial Update: Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is comparing Serplulimab to Nivolumab in resectable stage II-IIIA squamous non-small cell lung cancer, and recruitment is ongoing. S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Serplulimab (serplulimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Fudan University | Conditions: Resectable Stage II-IIIa Squamous NSCLC | Phase 2 | Status: RECRUITING